Unconventional ligands and modulators of nicotinic receptors

Journal of Neurobiology

Volumn 53, Issue 4, 2002, Pages 479-500

  Pereira, Edna F R ^a   Hilmas, Corey ^a   Santos, Mariton D ^a,b   Alkondon, Manickavasagom ^a   Maelicke, Alfred ^a,c   Albuquerque, Edson X ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Amyloid peptides; Galantamine; Glia; Kynurenic acid; Neurons; Nicotinic receptors; Psychotomimetics

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; CHOLINE; GALANTAMINE; GLUTAMIC ACID; KETAMINE; KYNURENIC ACID; LIGAND; NEUROSTEROID; NICOTINIC RECEPTOR; PHENCYCLIDINE; PSYCHEDELIC AGENT; TRYPTOPHAN;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; HUMAN; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

AMYLOID BETA-PROTEIN; ANESTHETICS; ANIMALS; CHOLINE; GALANTAMINE; HALLUCINOGENS; HUMANS; KYNURENIC ACID; LIGANDS; RECEPTORS, NICOTINIC; SEROTONIN; STEROIDS;

EID: 0036891169     PISSN: 00223034     EISSN: None     Source Type: Journal    
DOI: 10.1002/neu.10146     Document Type: Article

References (191)

1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. 1998. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189-202.
2. Albuquerque EX, Alkondon M, Pereira EFR, Castro NG, Schrattenholz A, Barbosa CTF, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke, A. 1997. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280:1117-1136.
3. Albuquerque EX, Aracava Y, Cintra WM, Brossi A, Schonenberger B, Deshpande SS. 1988. Structure-activity relationship of reversible cholinesterase inhibitors: Activation, channel blockade and stereospecificity of the nicotinic acetylcholine receptor-ion channel complex. Braz J Med Biol Res 21:1173-1196.
4. Albuquerque EX, Pereira EF, Castro NG, Alkondon M, Reinhardt S, Schroder H, Maelicke A. 1995. Nicotinic receptor function in the mammalian central nervous system. Ann NY Acad Sci 757:48-72.
5. Albuquerque EX, Pereira EFR, Mike A, Eisenberg HM, Maelicke A, Alkondon M. 2000. Neuronal nicotinic receptors in synaptic functions in humans and rats: Physiological and clinical relevance. Behav Brain Res 113:131-141.
6. Alkondon M, Albuquerque EX. 1993. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther 265:1455-1473.
7. Alkondon M, Albuquerque EX. 2001. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 86:3043-3055.
8. Alkondon M, Braga MFM, Pereira EFR, Maelicke A, Albuquerque EX. 2000a. α7 nicotinic acetylcholine receptors and modulation of GABAergic synaptic transmission in the hippocampus. Eur J Pharmacol 393:59-67.
9. Alkondon M, Pereira EFR, Albuquerque EX. 1998. Alpha-bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res 810:257-263.
10. Alkondon M, Pereira EFR, Almeida LEF, Randall WR, Albuquerque EX. 2000b. Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus. Neuropharmacology 39:2726-2739.
11. Alkondon M, Pereira EFR, Barbosa CTF, Albuquerque EX. 1997a. Neuronal nicotinic acetylcholine receptor activation modulates γ-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther 283:1396-1411.
12. Alkondon M, Pereira EFR, Cortes WS, Maelicke A, Albuquerque EX. 1997b. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in rat brain neurons. Eur J Neurosci 9:2734-2742.
13. Alkondon M, Pereira EFR, Eisenberg HM, Albuquerque EX. 1999. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 19:2693-2705.
14. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. 2000c. Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 20:66-75.
15. Almeida LEF, Pereira EFR, Alkondon M, Fawcett WP, Randall WR, Albuquerque EX. 2000. The opioid antagonist naltrexone inhibits activity and alters expression of α7 and α4β2 nicotinic receptors: Implications for smoking cessation programs. Neuropharmacology 39:2740-2755.
16. Aracava Y, Deshpande SS, Swanson KL, Rapoport H, Wonnacott S, Lunt G, Albuquerque EX. 1987. Nicotinic acetylcholine receptors in cultured neurons from the hippocampus and brain stem of the rat characterized by single channel recording. FEBS Lett 1987 222:63-70.
17. Arthur D, Levin ED. 2002. Chronic inhibition of alpha4beta2 nicotinic receptors in the ventral hippocampus of rats: Impacts on memory and nicotine response. Psychopharmacology (Berlin) 160:140-145.
18. Aubert I, Cecyre D, Gauthier S, Quirion R. 1996. Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. J Comp Neurol 369:31-55.
19. Backstrom T, Carstensen H, Sodergard R. 1976. Concentration of estradiol, testosterone and progesterone in cerebrospinal fluid compared to plasma unbound and total concentrations. J Steroid Biochem 7:469-472.
20. Banerjee C, Nyengaard JR, Wevers A, de Vos RA, Jansen Steur EN, Lindstrom J, Pilz K, Nowacki S, Bloch W, Schroder H. 2000. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - A stereological approach. Neurobiol Dis 7:666-672.
21. Baran H, Cairns N, Lubec B, Lubec G. 1996. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci 58:1891-1899.
22. Baran H, Jellinger K, Deecke L. 1999. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106:165-181.
23. Baulieu EE, Robel P. 1990. Neurosteroids: A new brain function? J Steroid Biochem Mol Biol 37:395-403.
24. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. 1990. Kynurenine pathway measurements in Huntington's disease striatum: Evidence for reduced formation of kynurenic acid. J Neurochem 55:1327-1339.
25. Belluardo N, Mudo G, Blum M, Fuxe K. 2000. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 113:21-34.
26. Berger F, Gage FH, Vijayaraghavan S. 1998. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 18:6871-6881.
27. Bergman SA. 1999. Ketamine: Review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 46:10-20.
28. Bertolino M, Kellar KJ, Vicini S, Gillis RA. 1997. Nicotinic receptor mediates spontaneous GABA release in the rat dorsal motor nucleus of the vagus. Neuroscience 79:671-681.
29. Bertrand D, Valera S, Bertrand S, Ballivet M, Rungger D. 1991. Steroids inhibit nicotinic acetylcholine receptors. Neuroreport 2:277-280.
30. Bijak M, Jarolimek W, Misgeld U. 1991. Effects of antagonists on quisqualate and nicotinic receptor-mediated currents of midbrain neurones in culture. Br J Pharmacol 102:699-705.
31. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T. 1997. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 764:173-178.
32. Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selik DE, Wolf V, Kosley RW Jr, Davis L, Vargas HM. 1996. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 277:728-738.
33. Broide RS, Leslie FM. 1999. The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 20:1-16.
34. Buhler AV, Dunwiddie TV. 2001. Regulation of the activity of hippocampal stratum oriens interneurons by alpha7 nicotinic acetylcholine receptors. Neuroscience 106:55-67.
35. Buisson B, Bertrand D. 1998. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:555-563.
36. Carter J, Lippa CF. 2001. Beta-amyloid, neuronal death and Alzheimer's disease. Curr Mol Med 1:733-737.
37. Cheeta S, Tucci S, File SE. 2001. Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacol Biochem Behav 70:491-496.
38. Chiappinelli VA, Giacobini E. 1978. Time course of appearance of alpha-bungarotoxin binding sites during development of chick ciliary ganglion and iris. Neurochem Res 3:465-478.
39. Clementi F, Fornasari D, Gotti C. 2000. Neuronal nicotinic receptors, important new players in brain functions. Eur J Pharmacol 393:3-10.
40. Coan EJ, Collingridge GL. 1987. Effects of phencyclidine, SKF 10,047 and related psychotomimetic agents on N-methyl-D-aspartate receptor mediated synaptic responses in rat hippocampal slices. Br J Pharmacol 91:547-556.
41. Coates KM, Flood P. 2001. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol 134:871-879.
42. Connolly J, Boulter J, Heinemann SF. 1992. Alpha 4-2 beta 2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs. Br J Pharmacol 105:657-666.
43. Coronas V, Durand M, Chabot JG, Jourdan F, Quirion R. 2000. Acetylcholine induces neuritic outgrowth in rat primary olfactory bulb cultures. Neuroscience 98:213-219.
44. Corpechot C, Young J, Calvel M, Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VV, Banner C, Sjovall J, et al. 1993. Neurosteroids: 3 alpha-hydroxy-5 alpha-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats. Endocrinology 133:1003-1009.
45. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. 2001. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49:175-184.
46. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E. 1999. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73:1590-1597.
47. Coyle J, Kershaw P. 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimer's disease. Biol Psychiatry 49:289-299.
48. Cozzi A, Carpenedo R, Moroni F. 1999. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 19:771-777.
49. Curtis L, Buisson B, Bertrand S, Bertrand D. 2002. Potentiation of human alpha4beta2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 61:127-135.
50. Dajas-Bailador FA, Soliakov L, Wonnacott S. 2002. Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem 80:520-530.
51. Damaj MI, Glassco W, Dukat M, Martin BR. 1999. Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther 291:1284-1291.
52. Dani JA, Ji D, Zhou F-M. 2001. Nicotinic mechanisms and nicotine addiction. Neuron 31:349-352.
53. Decker MW, Brioni JD, Bannon AW, Arneric SP. 1995. Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sci 56:545-570.
54. Dineley KT, Bell KA, Bui D, Sweatt JD. 2002. Betaamyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277:25056-25061.
55. Donaldson JO, Baselt RC. 1979. CSF phencyclidine. Am J Psychiatry 136:1341-1342.
56. Downie DL, Franks NP, Lieb WR. 2000. Effects of thiopental and its optical isomers on nicotinic acetylcholine receptors. Anesthesiology 93:774-783.
57. Downie DL, Vicente-Agullo F, Campos-Caro A, Bushell TJ, Lieb WR, Franks NP. 2002. Determinants of the anesthetic sensitivity of neuronal nicotinic acetylcholine receptors. J Biol Chem 277:10367-10373.
58. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. 2001. Alpha10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA 98:3501-3506.
59. Erhardt S, Oberg H, Engberg G. 2001. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 363:21-27.
60. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE. 1997. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci 17:7736-7745.
61. Falk L, Nordberg A, Seiger A, Kjaeldgaard A, Hellstrom-Lindahl E. 2002. The alpha7 nicotinic receptors in human fetal brain and spinal cord. J Neurochem 80:457-465.
62. Farber NB, Newcomer JW, Olney JW. 1998. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res 116: 421-437.
63. Ferreira A, Lu Q, Orecchio L, Kosik KS. 1997. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci 9:220-234.
64. Fischer U, Reinhardt S, Albuquerque EX, Maelicke A. 1999. Expression of functional alpha7 nicotinic acetylcholine receptor during mammalian muscle development and denervation. Eur J Neurosci 11:2856-2864.
65. Flood P, Ramirez-Latorre J, Role L. 1997. Alpha4beta2 neuronal nicotinic acetylcholine receptors in the central nervous system are inhibited by isoflurane and propofol, but alpha7-type nicotinic acetylcholine receptors are unaffected. Anesthesiology 86:859-865.
66. Franceschini D, Orr-Urtreger A, Yu W, Mackey LY, Bond RA, Armstrong D, Patrick JW, Beaudet AL, De Biasi M. 2000. Altered baroreflex responses in alpha7 deficient mice. Behav Brain Res 113:3-10.
67. Franceschini D, Paylor R, Broide R, Salas R, Bassetto L, Gotti C, De Biasi M. 2002. Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res Mol Brain Res 98:29-40.
68. Fratiglioni L, Wang HX. 2000. Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behav Brain Res 113:117-120.
69. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV. 1998. Synaptic potentials mediated via α-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 18:8228-8235.
70. Freedman R, Adams CE, Leonard S. 2000. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 20:299-306.
71. Fryer JD, Lukas RJ. 1999. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 72:1117-1124.
72. Furuya R, Oka K, Watanabe I, Kamiya Y, Itoh H, Andoh T. 1999. The effects of ketamine and propofol on neuronal nicotinic acetylcholine receptors and P2x purinoceptors in PC12 cells. Anesth Analg 88:174-180.
73. Garcia-Colunga J, Miledi R. 1999. Blockage of mouse muscle nicotinic receptors by serotonergic compounds. Exp Physiol 84:847-864.
74. Grant IS, Nimmo WS, McNicol LR, Clements JA. 1983. Ketamine disposition in children and adults. Br J Anaesth 55:1107-1111.
75. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. 1996. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 383:713-716.
76. Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X. 2001. Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J Neural Transm 108:1417-1433.
77. Hatton GI, Yang QZ. 2002. Synaptic potentials mediated by alpha 7 nicotinic acetylcholine receptors in supraoptic nucleus. J Neurosci 22:29-37.
78. Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A. 1999. Regional distribution of nicotinic receptor subunit mRNAs in human brain: Comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 66:94-103.
79. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. 2001. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: Physiopathological implications. J Neurosci 21:7463-7473.
80. Holz RW, Senter RA. 1981. Choline stimulates nicotinic receptors on adrenal medullary chromaffin cells to induce catecholamine secretion. Science 214:466-468.
81. Hosli E, Ruhl W, Hosli L. 2000. Histochemical and electrophysiological evidence for estrogen receptors on cultured astrocytes: Colocalization with cholinergic receptors. Int J Dev Neurosci 18:101-111.
82. Hyde TM, Crook JM. 2001. Cholinergic systems and schizophrenia: Primary pathology or epiphenomena? J Chem Neuroanat 22:53-63.
83. Ibanez-Tallon I, Miwa JM, Wang HL, Adams NC, Crabtree GW, Sine SM, Heintz N. 2002. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. Neuron 33:893-903.
84. Ji D, Dani JA. 2000. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J Neurophysiol 83:682-2690.
85. Ji D, Lape R, Dani JA. 2001. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31:131-141.
86. Karlin A. 2002. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 3:102-114.
87. Ke L, Lukas RJ. 1996. Effects of steroid exposure on ligand binding and functional activities of diverse nicotinic acetylcholine receptor subtypes. J Neurochem 67:1100-1112.
88. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. 2001. Alpha7 nicotinic receptor transduces signals to PI3 kinase to block Aβ-induced neurotoxicity. J Biol Chem 276:13541-13546.
89. Kirch DG, Gerhardt GA, Shelton RC, Freedman R, Wyatt RJ. 1987. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol 10:376-383.
90. 2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors. J Neurosci 17:9035-9047.
91. Le Novere N, Changeux JP. 1999. The ligand gated ion channel database. Nucleic Acids Res 27:340-342.
92. Léna C, Changeux JP. 1997. Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. Curr Opin Neurobiol 7:674-682.
93. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, Lee M, Adler L, Olincy A, Ross R, Freedman R. 2000. Smoking and schizophrenia: Abnormal nicotinic receptor expression. Eur J Pharmacol 393:237-242.
94. Levin ED, Bradley A, Addy N, Sigurani N. 2002. Hippocampal alpha7 and alpha4beta2 nicotinic receptors and working memory. Neuroscience 109:757-765.
95. Levin ED, Simon BB. 1998. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berlin) 138:217-230.
96. Lindstrom J. 1996. Neuronal nicotinic acetylcholine receptors. Ion Channels 4:377-450.
97. Lindstrom J. 2000. Acetylcholine receptors and myasthenia. Muscle Nerve 23:453-477.
98. Lindstrom J, Anand R, Gerzanich V, Peng X, Wang F, Wells G. 1996. Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res 109:125-137.
99. Lipton SA, Frosch MP, Phillips MD, Tauck DL, Aizenman E. 1988. Nicotinic antagonists enhance process outgrowth by rat retinal ganglion cells in culture. Science 239:1293-1296.
100. Liu Q, Kawai H, Berg DK. 2001. Beta-amyloid peptide blocks the response of alpha7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98:4734-4739.
101. Lu Y, Marks MJ, Collins AC. 1999. Desensitization of nicotinic agonist-induced [3H]gamma-aminobutyric acid release from mouse brain synaptosomes is produced by subactivating concentrations of agonists. J Pharmacol Exp Ther 291:1127-1134.
102. Maelicke A, Albuquerque EX. 1996. New approach to drug therapy of Alzheimer's dementia. Drugs Disc Today 1:53-59.
103. Mandelzys A, De Koninck P, Cooper E. 1995. Agonist and toxin sensitivities of ACh-evoked currents on neurons expressing multiple nicotinic ACh receptor subunits. J Neurophysiol 74:1212-1221.
104. Mansvelder HD, McGehee DS. 2000. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27:349-357.
105. Marshall DL, Redfern PH, Wonnacott S. 1997. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 68:1511-1519.
106. McMahon LL, Yoon KW, Chiappinelli VA. 1994. Nicotinic receptor activation facilitates GABAergic neurotransmission in the avian lateral spiriform nucleus. Neurosci 59:689-698.
107. Mike A, Castro NG, Albuquerque EX. 2000. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neurons. Brain Research 882:155-168.
108. Milart P, Mlynarczyk M, Sikorski R. 2000. Influence of maternal smoking on kynurenic acid concentrations in umbilical cord blood. Ginekol Pol 71:843-847.
109. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali A, Role LW, Heintz N. 1999. Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 23:105-114.
110. Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, Chase TN. 1986. GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol 9:257-263.
111. Moroni F. 1999. Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites. Eur J Pharmacol 375:87-100.
112. Moroni F, Russi P, Lombardi G, Beni M, Carla V. 1988. Presence of kynurenic acid in the mammalian brain. J Neurochem 51:177-180.
113. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. 2002. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110:199-211.
114. Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde TE, Younkin LH, Younkin SG, et al. 1994. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 36:903-911.
115. Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH. 1996. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22:369-381.
116. Nordberg A. 1999. PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 155:S53-S63.
117. Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S. 1992. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42:1702-1706.
118. Okonjo KO, Kuhlmann J, Maelicke A. 1991. A second pathway of activation of the Torpedo acetylcholine receptor channel. Eur J Biochem 200:671-677.
119. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, de Biasi M, Dani JA, Patrick JW, Beaudet AL. 1997. Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack α-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17:9165-9171.
120. Papke RL, Bencheriff M, Lippiello P. 1996. An evaluation of neuronal nicotinic acetylcholine receptor activation by quarternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci Lett 213:201-204.
121. Paradiso K, Sabey K, Evers AS, Zorumski CF, Covey DF, Steinbach JH. 2000. Steroid inhibition of rat neuronal nicotinic alpha4beta2 receptors expressed in HEK 293 cells. Mol Pharmacol 58:341-351.
122. Paradiso K, Zhang J, Steinbach JH. 2001. The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid. J Neurosci 21:6561-6568.
123. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM. 1997. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: Electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 283:1264-1275.
124. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A. 1998. Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: A behavioral characterization of Acra7-deficient mice. Learn Mem 5:302-316.
125. Pearce IA, Cambray-Deakin MA, Burgoyne RD. 1987. Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett 223:143-147.
126. Pellicciari R, Natalini B, Costantino G, Mahmoud MR, Mattoli L, Sadeghpour BM, Moroni F, Chiarugi A, Carpenedo R. 1994. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J Med Chem 37:647-655.
127. Pereira EFR, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, Albuquerque EX. 1994. Physostigmine and galanthamine: Probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylchoine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
128. Pereira EFR, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, Albuquerque EX. 1993. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
129. Perkins D, Pereira EFR, Gober M, Yarowsky PJ, Aurelian L. 2002. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway. J Virol 76:1435-1449.
130. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J. 2000. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393: 215-222.
131. Perry EK, Smith CJ, Court JA, Perry RH. 1990. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm Park Dis Dement Sect 2:149-158.
132. Pettit DL, Shao Z, Yakel JL. 2001. Beta-amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21:RC120.
133. Poeggeler B, Rassoulpour A, Guidetti P, Wu HQ, Schwarcz R. 1998. Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum. Dev Neurosci 20:146-153.
134. Pugh PC, Berg DK. 1994. Neuronal acetylcholine receptors that bind alpha-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J Neurosci 14:889-896.
135. Radcliffe KA, Dani JA. 1998. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 18:7075-7083.
136. Radcliffe KA, Fisher JL, Gray R, Dani JA. 1999. Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann NY Acad Sci 868:591-610.
137. Rakhilin S, Drisdel RC, Sagher D, McGehee DS, Vallejo Y, Green WN. 1999. Alpha-bungarotoxin receptors contain alpha7 subunits in two different disulfide-bonded conformations. J Cell Biol 146:203-218.
138. Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albuquerque EX. 1990. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther 254:71-82.
139. Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA. 2000. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 48:231-238.
140. Rice DP. 1999. The economic impact of schizophrenia. J Clin Psychiatry 60:4-6.
141. Robel P, Baulieu EE. 1995. Neurosteroids: Biosynthesis and function. Crit Rev Neurobiol 9:383-394.
142. Roerig B, Nelson DA, Katz LC. 1997. Fast synaptic signaling by nicotinic acetylcholine and serotonin 5-HT3 receptors in developing visual cortex. J Neurosci 17:8353-8362.
143. Role LW, Berg DK. 1996. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:1077-1085.
144. Romano SJ, Pugh PC, McIntosh JM, Berg DK. 1997. Neuronal-type acetylcholine receptors and regulation of alpha 7 gene expression in vertebrate skeletal muscle. J Neurobiol 32:69-80.
145. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A. 2000. Galantamine is an allosterically potentiating ligand of the human α4β2 nAChR. Acta Neurol Scand Suppl 176:68-73.
146. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX. 2002. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
147. Schalling D, Waller D. 1980. Psychological effects of tobacco smoking. Acta Physiol Scand Suppl 479:53-56.
148. Scharfman HE, Hodgkins PS, Lee SC, Schwarcz R. 1999. Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. Neurosci Lett 274:111-114.
149. Schrattenholz A, Godovac-Zimmermann J, Schafer H-J, Albuquerque EX, Maelicke A. 1993. Photoaffinity labeling of Torpedo acetylcholine receptors by physostigmine. Eur J Biochem 216:671-677.
150. Schrattenholz A, Pereira EFR, Roth U, Weber KH, Albuquerque EX, Maelicke A. 1996. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
151. Schroder B, Reinhardt-Maelicke S, Schrattenholz A, McLane KE, Kretschmer A, Conti-Tronconi BM, Maelicke A. 1994. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide. J Biol Chem 269:10407-10416.
152. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. 2001. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-530.
153. Sgard F, Charpantier E, Bertrand S, Walker N, Caput D, Graham D, Bertrand D, Besnard F. 2002. A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. Mol Pharmacol 61:150-159.
154. Sharma G, Vijayaraghavan S. 2001. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 98:4148-4153.
155. Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. 1985. The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol Pharmacol 28:527-538.
156. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. 1985. Comparison of the actions of carbamate anti-cholinesterases on the nicotinic acetylcholine receptor. Mol Pharmacol 27:343-348.
157. Sihver W, Gillberg PG, Svensson AL, Nordberg A. 1999. Autoradiographic comparison of [3H](-)nicotine, [3H]cy-tisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience 94:685-696.
158. Steinlein OK, Mulley JC, Propping P, Wallace RH, Philipps HA, Sutherland GR, Scheffer IE, Berkovic SF. 1995. A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 11:201-203.
159. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM. 1996. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152-162.
160. Stone TW. 1993. Neuropharmacology of quinolinic and kynurenic acid. Pharmacol Rev 45:309-379.
161. Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskic V, Pereira EFR, Albuquerque EX, Methfessel C, Maelicke A. 1995. Physostigmine, galanthamine and codeine act as "noncompetitive nicotinic receptor agonists" on clonal rat pheochromocytoma cells. Eur J Pharmacol 290:207-219.
162. Storm-Mathisen, J. 1977. Localization of putative transmitters in the hippocampal formation: With a note on the connections to septum and hypothalamus. Ciba Found Symp 58:49-86.
163. Sun A, Cheng J. 1999. Novel targets for therapeutic intervention against ischemic brain injury. Clin Neuropharmacol 22:164-171.
164. Tapiola T, Pirttila T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H. 2000. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21:735-740.
165. Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D. 2002. The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 57:133-150.
166. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. 2000. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20:1386-1392.
167. Tsai G, Coyle JT. 2002. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
168. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO Jr, Schwarcz R. 1988. Identification and quantification of kynurenic acid in human brain tissue. Brain Res 454:164-169.
169. Urenjak J, Obrenovitch TP. 2000. Kynurenine 3-hydroxylase inhibition in rats: Effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum. J Neurochem 75:2427-2433.
170. Valera S, Ballivet M, Bertrand D. 1992. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 89:9949-9953.
171. Verbitsky M, Rothlin CV, Katz E, Elgoyhen AB. 2000. Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor. Neuropharmacology 39:2515-2524.
172. Vesce S, Bezzi P, Volterra A. 1999. The highly integrated dialogue between neurons and astrocytes in brain function. Sci Prog 82:251-270.
173. Vidal C, Changeux JP. 1989. Pharmacological profile of nicotinic acetylcholine receptors in the rat prefrontal cortex: An electrophysiological study in a slice preparation. Neuroscience 29:261-270.
174. Violet JM, Downie DL, Nakisa RC, Lieb WR, Franks NP. 1997. Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics. Anesthesiology 86:866-874.
175. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. 2000a. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626-5632.
176. Wang HY, Lee DH, Davis CB, Shank RP. 2000b. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75:1155-1161.
177. Watanabe I, Andoh T, Furuya R, Sasaki T, Kamiya Y, Itoh H. 1999. Depressant and convulsant barbiturates both inhibit neuronal nicotinic acetylcholine receptors. Anesth Analg 88:1406-1411.
178. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. 2002. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22:1858-1867.
179. Whiteaker P, Marks MJ, Grady SR, Lu Y, Picciotto MR, Changeux JP, Collins AC. 2000. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. Eur J Pharmacol 393:123-135.
180. Wonnacott S. 1997. Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-98.
181. Wright CI, Geula C, Mesulam MM. 1993. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Ann NY Acad Sci 695:65-68.
182. Wu HQ, Bara H, Ungerstedt U, Schwarcz R. 1992. Kynurenic acid in the quinolinate-lesioned rat hippocampus: Studies in vitro and in vivo. Eur J Neurosci 4:1264-1270.
183. Wu HQ, Rassoulpour A, Schwarcz R. 2002. Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum. J Neural Transm 109:239-249.
184. Yamada S, Kagawa Y, Isogai M, Takayanagi N, Hayashi E. 1986. Ontogenesis of nicotinic acetylcholine receptors and presynaptic cholinergic neurons in mammalian brain. Life Sci 38:637-644.
185. Yamakura T, Chavez-Noriega LE, Harris RA. 2000. Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 92:1144-1153.
186. Zhang ZW, Coggan JS, Berg DK. 1996. Synaptic currents generated by neuronal acetylcholine receptors sensitive to alpha-bungarotoxin. Neuron 17:1231-1240.
187. Zhang M, Wang YT, Vyas DM, Neuman RS, Bieger D. 1993. Nicotinic cholinoceptor-mediated excitatory postsynaptic potentials in rat nucleus ambiguus. Exp Brain Res 96:83-88.
188. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. 1999. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 18:1235-1244.
189. Zwain IH, Yen SS. 1999. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology 140:3843-3852.
190. Zwart R, van Kleef RG, Gotti C, Smulders CJ, Vijverberg HPM. 2000. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem 75:2492-2500.
191. Zwart R, Vijverberg HPM. 2000. Potentiation and inhibition of neuronal alpha4beta4 nicotinic acetylcholine receptors by choline. Eur J Pharmacol 393:209-214.